What 8 Analyst Ratings Have To Say About Globus Medical
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have published ratings on Globus Medical (NYSE:GMED), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 13.36% to $76.38. Analysts have raised their price targets, reflecting positive market conditions and company performance. Despite impressive revenue growth, Globus Medical faces challenges in profitability and asset utilization.
August 07, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Globus Medical (NYSE:GMED) has received mixed ratings from 8 analysts over the past three months, with a notable increase in the average 12-month price target by 13.36% to $76.38. Analysts have raised their price targets, indicating positive sentiment towards the company's market performance. However, the company faces challenges in profitability and asset utilization despite strong revenue growth.
The increase in the average price target and the positive sentiment from analysts suggest a likely short-term upward movement in GMED's stock price. However, the company's challenges in profitability and asset utilization may temper the extent of this positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100